company background image
VERU logo

Veru NasdaqCM:VERU Stock Report

Last Price

US$0.63

Market Cap

US$92.0m

7D

-11.9%

1Y

-12.4%

Updated

24 Dec, 2024

Data

Company Financials +

VERU Stock Overview

A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). More details

VERU fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Veru Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Veru
Historical stock prices
Current Share PriceUS$0.63
52 Week HighUS$1.92
52 Week LowUS$0.36
Beta-0.55
1 Month Change-6.90%
3 Month Change-19.05%
1 Year Change-12.43%
3 Year Change-89.54%
5 Year Change-81.24%
Change since IPO-90.51%

Recent News & Updates

Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?

Dec 18
Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?

Recent updates

Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?

Dec 18
Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?

Is Veru (NASDAQ:VERU) A Risky Investment?

Aug 07
Is Veru (NASDAQ:VERU) A Risky Investment?

What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

Jul 17
What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You

Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

May 31
Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Jan 09
The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Aug 16
Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Apr 17
Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 14
Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Jan 13
Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Nov 13
Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Oct 17

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Sep 26
Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Veru FDA AdCom meeting for COVID-19 therapy postponed

Sep 19

Veru: A Good Combination Of A Stable Business And Growth Opportunities

Sep 13

Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy

Sep 07

Shareholder Returns

VERUUS Personal ProductsUS Market
7D-11.9%-3.1%-0.4%
1Y-12.4%-24.7%24.8%

Return vs Industry: VERU exceeded the US Personal Products industry which returned -24.7% over the past year.

Return vs Market: VERU underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is VERU's price volatile compared to industry and market?
VERU volatility
VERU Average Weekly Movement9.5%
Personal Products Industry Average Movement8.2%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: VERU has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VERU's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1971210Mitch Steinerverupharma.com

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death.

Veru Inc. Fundamentals Summary

How do Veru's earnings and revenue compare to its market cap?
VERU fundamental statistics
Market capUS$91.99m
Earnings (TTM)-US$37.80m
Revenue (TTM)US$16.89m

5.4x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VERU income statement (TTM)
RevenueUS$16.89m
Cost of RevenueUS$11.03m
Gross ProfitUS$5.85m
Other ExpensesUS$43.66m
Earnings-US$37.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin34.67%
Net Profit Margin-223.86%
Debt/Equity Ratio30.6%

How did VERU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:58
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Veru Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William WoodB. Riley Securities, Inc.
Brandon FolkesCantor Fitzgerald & Co.
Yi ChenH.C. Wainwright & Co.